Clinical Trials Using Nilotinib
Clinical trials are research studies that involve people. The clinical trials on this list are studying Nilotinib. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL
The design of a phase I, open label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent ABL001 in CML and Ph+ ALL patients who are relapsed or refractory to or are intolerant of TKIs, and of ABL001+Nilotinib, ABL001+Imatinib and ABL001+Dasatinib in Ph positive CML patients who are relapsed or refractory to TKIs.
Location: 4 locations
Ruxolitinib Phosphate and Nilotinib in Treating Patients with Chronic Phase Chronic Myelogenous Leukemia Who Have Received Tyrosine Kinase Inhibitor Therapy and Achieved a Major Molecular Remission
This phase I / II trial studies the side effects and best dose of ruxolitinib phosphate when given together with nilotinib and to see how well they work in treating patients with chronic phase chronic myelogenous leukemia that is under good, but not perfect control on tyrosine kinase inhibitor therapy. Ruxolitinib phosphate and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Location: 2 locations
Dasatinib or Nilotinib Followed by Imatinib Mesylate in Treating Patients with Newly Diagnosed, Previously Untreated, Chronic Phase Chronic Myeloid Leukemia
This phase II trial studies how well dasatinib, nilotinib, and imatinib mesylate works in treating patients with newly diagnosed, previously untreated chronic myeloid leukemia in which fewer than 10% of the cells in the blood and bone marrow are blast cells (immature blood cells) (chronic phase). Dasatinib, nilotinib, and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Location: Emory University Hospital / Winship Cancer Institute, Atlanta, Georgia
Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
This is a 2 part study. The goal of the first part of this clinical research study is to find the highest tolerable dose of ruxolitinib that can be given with a TKI that you are already taking (such as gleevec, sprycel or nilotinib) as part of your standard of care treatment. The goal of the second part of this study is to learn if this drug combination can help to control CML. Although you have a good response to therapy, the disease is still detectable at low levels (this is called "minimal residual disease"). Researchers believe that eliminating all detectable evidence of disease may decrease the chances that the leukemia will ever come back. The safety of the drug combination will also be studied in both parts. Ruxolitinib is designed to block a protein called Jak2 that may help keep some leukemia cells alive even with TKI therapy. Blocking this protein may cause the cells to die. This is an investigational study. TKIs are approved for the treatment of CML and are given as part of your standard of care, even if you do not participate in this study. Ruxolitinib is FDA approved and commercially available for the treatment of patients with myelofibrosis. The combination of these drugs to treat CML is investigational. Up to 48 patients will take part in this study. All will be enrolled at MD Anderson.
Location: M D Anderson Cancer Center, Houston, Texas
Targeted Therapy in Treating Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
This phase II trial studies how well targeted therapy works in treating patients with acute lymphoblastic leukemia or acute myelogenous leukemia that has come back after a period of improvement or does not respond to treatment. Testing patients' blood or bone marrow to find out if their type of cancer may be sensitive to a specific drug may help doctors choose more effective treatments. Dasatinib, nilotinib, sunitinib malate, sorafenib tosylate, and ponatinib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving targeted therapy based on cancer type may be an effective treatment for acute lymphoblastic leukemia or acute myelogenous leukemia.
Location: 4 locations
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
The purpose of this study is to allow continued use of nilotinib in patients who are on nilotinib treatment in a Novartis-sponsored, Oncology Clinical Development & Medical Affairs (CD&MA) study and are benefiting from the treatment as judged by the investigator
Location: See Clinical Trials.gov
Nilotinib and Paclitaxel in Treating Patients with Refractory Solid Tumors
This phase I trial studies the side effects and best dose of nilotinib and paclitaxel in treating patients with solid tumors that do not respond to treatment (refractory). Nilotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nilotinib and paclitaxel together may work better in treating patients with refractory solid tumors because nilotinib may block enzymes that would remove paclitaxel from within the cancer cells where it needs to be for anticancer activity.
Location: 2 locations
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and dasatinib, imatinib mesylate, or nilotinib may work better in treating patients with chronic myeloid leukemia.
Location: ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania
Nilotinib and Cetuximab in Treating Patients With Solid Tumors That Can Be Treated With Cetuximab
This phase I trial studies the side effects and the best dose of nilotinib when given together with cetuximab in treating patients with solid tumors that can be treated with cetuximab. Nilotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving nilotinib and cetuximab may be an effective treatment for solid tumors.
Location: MedStar Georgetown University Hospital, Washington, District of Columbia